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Dapagliflozin rescues endoplasmic 
reticulum stress-mediated cell 
death
Ryo Shibusawa1, Eijiro Yamada1, Shuichi Okada1, Yasuyo Nakajima1, Claire C. Bastie2, 
Akito Maeshima3, Kyoichi Kaira4 & Masanobu Yamada1
The new type 2 diabetes drug, dapagliflozin, reduces blood glucose levels and body weight by 
inhibiting sodium glucose transporter 2 (SGLT2) in proximal tubular cells. SGLT2 inhibitors might 
modulate glucose influx into renal tubular cells, thereby regulating the metabolic conditions that cause 
endoplasmic reticulum (ER) stress in the cells. In this study, we examined the effect of dapagliflozin 
on ER stress in the HK-2 proximal tubular cell line and in the kidney of db/db mice to characterise its 
function in diabetic nephropathy (DN). We found that dapagliflozin regulated ER stress-mediated 
apoptosis in vitro and in vivo. Only the elf2α-ATF4-CHOP pathway was regulated under these 
conditions. Notably, the drug rescued C2 ceramide-induced ER stress-mediated apoptosis and ER 
stress-mediated apoptosis, which might occur in DN, in db/db mice. Our study shows a novel role 
for dapagliflozin as an inhibitor of ER stress and suggests that dapagliflozin might be useful for the 
prevention of DN.
The number of patients with diabetes has increased globally, partly due to changes in dietary habits and a lack 
of exercise1–3. Diabetes leads to an array of additional complications, and the disease and its prevention have 
become a worldwide priority4. One of the major complications of diabetes is diabetic nephropathy (DN), which 
is the leading cause of end-stage renal disease5,6. Several studies have shown that the diabetic kidney is exposed to 
various environmental stressors that may cause endoplasmic reticulum (ER) stress5,6.
The ER is the major site for protein folding7,8. When protein loading exceeds its capacity, unfolded pro-
tein response (UPR) is activated to suppress protein synthesis and increase both the ER folding capacity and 
misfolded protein degradation, resulting in the restoration of cellular homeostasis7. If the stress response is 
prolonged or beyond ER folding capacity, it may lead to cell death7. UPR is mediated by three canonical path-
ways: RNA-dependent protein kinase-like ER kinase (PERK), activating transcription factor 6 (ATF6), and 
inositol-requiring enzyme 1 (IRE1) pathways7. PERK is present in the ER and its phosphorylation at Ser51 of 
eukaryotic translation initiation factor 2α (eIF2α) inhibits protein translation7,9. Notably, ATF4 activated by 
phosphorylation of eIF2α initiates the transcription of CCAAT/enhancer-binding protein-homologous protein 
(Chop/Gadd153), which is critical in ER stress-induced apoptosis7,9,10. Although ATF6 also exists in the ER, it is 
transported to the Golgi apparatus under stress conditions and cleaved by site-1 and site-2 proteases7,11. Cleaved 
ATF6 enters the nucleus and transcribes adaptive chaperons such as Bip/GRP787,11. IRE1 exerts endoribonuclease 
and kinase activities7,12. The endoribonuclease activity of IRE1 cleaves the X-box binding protein 1 (XBP1) to 
generate spliced XBP1 (XBP1s), a transcription factor involved in the survival response7,12. It has been shown that 
the IRE1α-XBP1 pathway plays a role in insulin resistance by activating JNK and suppressing insulin signalling; 
however, the relationship between ER stress and diabetic complications is still largely unknown13–15.
Ceramides are important molecules involved in sphingolipid metabolism and play critical roles in the regu-
lation of various cellular functions, including cell proliferation, differentiation, migration, and apoptosis16,17. The 
short side chain C2 ceramide easily invades cells, exerts physiological activity, and enhances caspase-dependent 
apoptosis17. It has been shown that plasma C2 ceramide levels also increase in diabetes18. They play an important 
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pathophysiological role not only in the development of diabetes itself but also in diabetic complications19–22. 
C2 ceramide induces apoptosis by multiple mechanisms, namely activation of the extrinsic apoptotic pathway, 
increasing cytochrome c release, generation of free radicals, and induction of ER stress19,20.
Glomerular damage is considered the main characteristic in the kidneys of patients with DN. However, it was 
recently suggested that alterations in the renal tubule might also contribute to the pathogenesis of DN23. Notably, 
the novel type 2 diabetes drug dapagliflozin reduces blood glucose and body weight by inhibiting sodium glucose 
transporter 2 (SGLT2) in the proximal tubular cells24. We hypothesised that modulation of SGLT2 activity might 
affect glucose influx into renal tubular cells. Inhibiting SGLT2 with dapagliflozin may regulate the metabolic con-
ditions that cause ER stress in these cells25. Therefore, in this study, we examined the effect of the SGLT2 inhibitor 
dapagliflozin on UPR in both the in vitro proximal tubular cell line HK-2 and in vivo.
Results
Dapagliflozin mediates glucose influx and ER stress in HK2 cells. Dapagliflozin inhibits SGLT2-
mediated renal glucose reabsorption in renal proximal tubular epithelial cells, thereby lowering the plasma blood 
glucose levels in patients with diabetes10,12,13. To identify additional functions of SGLT2, we used HK2 cells, an 
in vitro cell model of renal proximal tubular epithelial cells. First, we performed a series of dose-response and 
time course experiments to determine the effects of dapagliflozin on glucose levels in HK2 cells. Since a maxi-
mum plasma concentration (Cmax) of dapagliflozin of approximately 0.5 μM and 0.2–20 μM was used in previ-
ous studies, we initially choose 0.5–2.0 μM dapagliflozin. We found that intracellular glucose concentrations in 
cells treated with 2 μM dapagliflozin for 24–48 h decreased by 20%, compared to those in control (non-treated) 
cells (Fig. 1a). Since the effect of dapagliflozin was maximum at this condition, we decided to use it for all in 
vitro experiments. Notably, glucose influx measured with tracers decreased by around 40% under this condi-
tion (Fig. 1b). As glucose influx could potentially mediate ER stress in cells and tissues, we next examined the 
markers of ER stress in dapagliflozin-treated HK-2 cells. We first evaluated the basal level of ER stress. Since the 
basal level of ER stress might depend on cell confluency, we plated different cell numbers on 24 wells and found 
that the phosphorylation of elf2α, a marker for ER stress, was the maximum 48 h after we plated 1 × 106 cells in 
24 wells (Supplementary Fig. 1). Under these conditions, dapagliflozin decreased the phosphorylation of elf2α 
(Fig. 2a,b). To confirm this, we examined the downstream targets of elf2α. As shown in Fig. 2c, the decrease in 
ATF4 expression levels in dapagliflozin-treated HK2 cells was parallel to the decrease in eIf2α phosphorylation 
levels. In contrast, dapagliflozin had no effect on total and cleaved forms of ATF6 (Fig. 2d,e) or phosphorylation 
of IRE1α (Fig. 2d,f), indicating that it mediated ER stress only through the elf2α pathway.
CHOP has recently been reported as a downstream target of elf2α and has been described as a marker of 
ER-mediated apoptosis7,9,10. As shown in Fig. 2g, CHOP expression levels also decreased in dapagliflozin-treated 
HK2 cells. Because CHOP expression levels decreased, we next examined caspase-3 activity to determine 
Figure 1. Dapagliflozin regulates glucose influx into HK-2 renal proximal tubular epithelial cells. (a) HK2 cells 
were incubated with the indicated dapagliflozin concentration for the indicated times and were collected for 
glucose analysis. Glucose concentration in HK2 cells was assessed using the PicoProbe Glucose Fluorometric 
Assay Kit (BioVision). P < 0.05 (n = 3–5). (b) Glucose influx in HK2 cells incubated with 2 µM dapagliflozin for 
36 h was measured using the 2-Deoxyglucose Uptake Measurement Kit (COSMO BIO Co. Ltd., Tokyo Japan) 
according to the manufacturer’s instructions.
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the apoptotic status of these cells. As shown in Fig. 2h, we observed a 20% reduction in caspase-3 activity in 
dapagliflozin-treated cells. This paralleled the reduction in glucose influx, phosphorylation of elF2α, and expres-
sion of CHOP, suggesting that dapagliflozin might regulate apoptosis through the elf2α-CHOP axis in HK2 cells.
Figure 2. Dapagliflozin regulates unfolded protein response in HK-2 cells. (a) HK2 cells were incubated 
with 2 μM dapagliflozin for 36 h and collected for protein expression analysis. These immunoblots are 
representative of n = 5 experiments performed independently. (b) Signal quantification of the expression levels 
for S51 phosphorylation of elf2α normalised with total elf2α levels. (c) HK2 cells were incubated with 2 μM 
dapagliflozin for 36 h, and the ATF4 mRNA expression levels were determined by qRT-PCR (n = 5 independent 
experiments). (d) HK2 cells were incubated with 2 μM dapagliflozin for 36 h, collected for protein analysis, and 
immunoblotted for the indicated proteins. These are representative immunoblots independently performed 
five times. (e,f) Signal quantification of the expression levels of ATF6 normalised with tubulin-α (e) and the 
expression levels for S724 phosphorylation of IRE1α normalised with total IRE1α levels (f). (g) HK2 cells were 
incubated with 2 μM dapagliflozin for 36 h, and the expression level of CHOP mRNA was determined by qRT-
PCR (n = 5 independent experiments). (h) HK2 cells were incubated with 2 μM dapagliflozin for 36 h and 
caspase-3 activity levels were measured using a caspase-3 fluorescence assay kit (MBL) (n = 5 independent 
experiments).
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The eIF2α pathway is critical for the effects of dapagliflozin on ER stress in HK2 cells. To 
examine whether the effects of dapagliflozin were the result of reduced glucose uptake or a direct effect of 
dapagliflozin, the medium of HK-2 cells was supplemented with different concentrations (0–10 mM) of 
D-galactose before the analyses of elf2α and CHOP expression. As shown in Fig. 3a, dapagliflozin reduced the 
phosphorylation of elf2α, except in the presence of 10 mM D-galactose, indicating that the effect of dapagli-
flozin was due to reduced glucose uptake. To investigate whether the elf2α pathway is critical for the effect of 
dapagliflozin on ER stress, siRNA-mediated knockdown of elf2α was performed, and ATF4 and CHOP expres-
sion was determined. As shown in Fig. 3c,d, siRNA-mediated knockdown of elf2α reduced the basal levels of 
ATF4 and CHOP. Notably, the effects of dapagliflozin on ATF4 and CHOP were completely abolished under 
these conditions, indicating that the elf2α pathway plays a crucial role in mediating the effects of dapagliflozin 
(Fig. 3c,d).
Dapagliflozin rescued C2 ceramide-induced ER stress through the elf2α-CHOP pathway. 
Our data suggested that dapagliflozin mediated apoptosis through ER stress; however, whether dapagliflozin 
could be a key factor in the prevention of diabetic kidney disease remained to be determined. Therefore, to 
confirm the effect of dapagliflozin on ER stress and to examine its effect on the kidney in metabolic diseases, 
we used C2 ceramide, which not only induces ER stress but also acts as a pathogen in metabolic diseases19–22. 
As shown in Fig. 4, dapagliflozin had no effect on GLUT2 and SGLT2 expression (Fig. 4a–c) but decreased 
elf2α phosphorylation (Fig. 4a,d) and ATF4 expression (Fig. 4e). C2 ceramide enhanced elf2α phosphorylation 
(Fig. 4a,d) and ATF4 expression (Fig. 4e). Dapagliflozin partially reduced these effects, suggesting that it might 
alleviate C2 ceramide-induced ER stress. Notably, C2 ceramide-induced CHOP expression and caspase-3 
activity were also inhibited by dapagliflozin (Fig. 5a,b). C2 ceramide reduced cell number and protein amounts 
in HK-2 cells, indicating cell death. However, dapagliflozin rescued the effect of C2 ceramide (Fig. 5c,d) by 
Figure 3. Dapagliflozin regulates unfolded protein response through the eIF2α pathway in HK-2 cells. (a) HK2 
cells were treated with 2 μM dapagliflozin for 36 h with varying concentrations of D-galactose. Immunoblotting 
was performed with the indicated antibodies. (b) HK2 cells were transfected by siRNA for elf2α and incubated 
with 2 μM dapagliflozin for 36 h. Immunoblotting was performed with the indicated antibodies. (c,d) HK2 cells 
were transfected by siRNA for elf2α and incubated with 2 μM dapagliflozin for 36 h. The mRNA expression 
levels of ATF4 and CHOP were determined by qRT-PCR (n = 5 independent experiments).
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regulating apoptosis and necrosis (Fig. 5e,f). These data indicate that dapagliflozin might attenuate the meta-
bolic state that induces renal cell death and exhibit beneficial effects in preventing DN, independently of blood 
glucose reduction.
Dapagliflozin ameliorates ER stress in the kidney of db/db mice in vivo. Our data suggested that 
dapagliflozin ameliorated glucose-mediated ER stress and apoptosis in HK2 cells, the model of renal proximal 
tubular epithelial cells in vitro. To further examine the effects of dapagliflozin, we repeated these experiments 
using kidneys of db/db mice, a mouse model of type 2 diabetes26,27. Previous reports have shown that ER stress 
is upregulated in the kidney of db/db mice28,29. To explore the effects of dapagliflozin on ER stress in the kid-
ney of db/db mice, the drug was administered orally to the animals every day for 1 week. Similarly to previous 
studies30,31, we did not observe any significant decrease in body weight after only 1 week of treatment (Fig. 6a). 
However, blood glucose levels significantly decreased with no significant change in the expression level of SGLT2 
(Fig. 6b,c). Notably, in these conditions, dapagliflozin decreased elf2α phosphorylation (Fig. 6d,e) and ATF4 
expression independently of body weight change (Fig. 6f). In contrast, dapagliflozin had no effect on total and 
cleaved forms of ATF6 (Fig. 6g,h) or phosphorylation of IRE1α (Fig. 6g,i). ATF4 and CHOP expression and 
Figure 4. Dapagliflozin rescued C2 ceramide-induced ER stress in HK2 cells. (a) HK2 cells were treated with 
2 μM dapagliflozin for 36 h with or without 7.5 ng/mL C2 ceramide, and immunoblotting was performed 
with the indicated antibodies (b,c). Signal quantification of the expression levels of GLUT2 (b) and SGLT2 (c) 
normalised with tubulin-α levels. (d) Signal quantification of the expression levels of S51 phosphorylation of 
elf2α normalised with total elf2α levels. (e) HK2 cells were incubated with 2 μM dapagliflozin for 36 h, and the 
mRNA expression levels of ATF4 were determined by qRT-PCR (n = 5 independent experiments).
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caspase-3 activity were also inhibited by dapagliflozin (Fig. 7a–c). These data indicate that dapagliflozin amelio-
rates ER stress in the kidney of db/db mice in vivo and has beneficial effects in preventing DN.
Discussion
SGLT2 inhibitors are novel type 2 diabetes drugs that reduce blood glucose by inhibiting SGLT2 in the proximal 
tubules24,25,32. Dapagliflozin is an SGLT2 inhibitor that is rapidly absorbed after oral administration. Its maximum 
plasma concentration (Cmax) is approximately 0.5 µM. The working concentration of dapagliflozin has been 
reported to be 0.1–20 µM in HK-2 cells33–37. In this study, we treated HK-2 cells with 2 μM dapagliflozin based on 
the findings reported in previous studies.
Figure 5. Dapagliflozin rescued C2 ceramide-induced cell death in HK2 cells. (a) HK2 cells were incubated 
with 2 μM dapagliflozin for 36 h with or without 7.5 ng/ml C2 ceramide, and the expression levels of CHOP 
mRNA were determined by qRT-PCR (n = 5 independent experiments). (b) HK2 cells were treated with 2 μM 
dapagliflozin for 36 h with or without 7.5 ng/ml C2 ceramide, and caspase-3 activity levels were determined 
(n = 5 independent experiments). (c,d) HK2 cells were treated with 2 μM dapagliflozin for 48 h with or without 
7.5 ng/ml C2 ceramide, and the cells were subjected to microscopic observation (c) and protein assay (d). These 
are representative images from experiments independently performed five times. (e), (f) HK2 cells were treated 
with 2 μM dapagliflozin for 48 h with or without 7.5 ng/ml C2 ceramide, and apoptosis and necrosis assay was 
performed using a Cell Death Detection ELISAplus (Roche, Indianapolis, IN).
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Changes in glucose influx into the cells might contribute to the metabolic conditions that enhance ER stress 
in DN. Therefore, we hypothesised that inhibiting SGLT2 might reduce ER stress and protect against proximal 
tubular cell death. It has been reported that increasing glucose influx into cells might induce but also decrease ER 
Figure 6. Effect of dapagliflozin on ER stress-induced cell death in vivo. (a) Body weights of db/db mice 
administered oral dapagliflozin every day for 1 week. (b) Blood glucose levels of db/db mice administered 
dapagliflozin. (c) SGLT2 mRNA levels in the kidney of db/db mice were determined by qRT-PCR (n = 5 
independent experiments). (d,g) The kidneys of db/db mice were utilised for protein expression analysis. These 
immunoblots are representative of n = 5 experiments performed independently. (e) Signal quantification of 
the expression levels of S51 phosphorylation of elf2α normalised with total elf2α. (f) Expression levels of ATF4 
mRNAs were determined by qRT-PCR (n = 5 independent experiments). (h,i) Signal quantification of the 
expression levels of ATF6 normalised with tubulin-α (h) and the expression levels of S724 phosphorylation of 
IRE1α normalised with total IRE1α (i).
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stress38–40. In this study, we demonstrated that dapagliflozin regulates ER stress by reducing glucose concentration 
as well as glucose influx into HK-2 cells and that it suppresses apoptosis via regulation of the elf2α-ATF4-CHOP 
pathway. The fact that glucose depletion does not induce ER stress but instead ameliorates it in renal cells may 
appear counter-intuitive. However, several reports have indicated that renal tubular cells are easily subjected to 
oxidative stress and ER stress-mediated cell death. As high glucose potentially upregulates oxidative stress, this 
might be one plausible mechanism by which glucose depletion ameliorates ER stress in renal tubular cells41–43. 
Knockdown of elf2α counteracted the effect of dapagliflozin. It was shown that the anaesthetic drug propofol 
inhibits PERK-eIF2α-ATF4-CHOP activation under ER stress, caspase-3 activation, and apoptosis, whereas it 
activates the IRE1-XBP1 and ATF6 pathways44. These data indicate that the regulation of ER stress is largely 
dependent on the stimulus itself and pathways regulating ER stress and apoptosis vary with the nature of cells 
and/or pathology. Our study suggests that the elf2α-ATF4-CHOP pathway regulates ER stress in HK2 proximal 
tubular cells and in the kidney of db/db mice.
ER stress has been associated with many diseases including neurodegenerative disorders, type 2 diabetes, 
atherosclerosis, or cancer45. CHOP is a key protein playing a role in ER stress-induced apoptosis and one of the 
transcription factors regulated by both PERK-elf2α-ATF4 and ATF646. IRE1α also induces apoptosis through 
caspases and ASK1-JNK. A positive correlation was observed between the enhanced CHOP expression and 
cell apoptosis in tubule epithelial cells47. Activation of PERK may be a key event in the regulation of CHOP 
expression48. Our findings were consistent with these data and indicated that dapagliflozin might regulate ER 
stress-induced apoptosis through the PERK-CHOP axis.
Ceramides are generated either by the hydrolysis of sphingomyelin catalysed by sphingomyelinase or by de 
novo synthesis in response to diverse stimuli. Under apoptotic stimuli, ceramides are generated by de novo syn-
thesis and promote activation of caspases49,50. Notably, ceramides are induced in renal proximal tubular cells in 
response to hydrogen peroxide or hypoxia/reperfusion51,52. When ceramide generation was inhibited using SPT 
inhibitors and ceramide synthase inhibitors, a reduction in tubular epithelial cell death was observed22. Many 
studies on lipid metabolism in DN have been reported recently36. For example, AdipoRon, a therapeutic agent 
against DN, ameliorates renal ceramide-induced lipotoxicity in type 2 diabetes mellitus21. Additionally, investi-
gating the role of ceramide is one of the major fields of study in DN, and researchers have reported excessive cer-
amide formation in the pathobiological condition of DN19–22. Therefore, we examined the effects of dapagliflozin 
on ER stress and apoptosis after C2 ceramide treatment and demonstrated that dapagliflozin alleviated renal cell 
death induced by metabolic conditions (i.e. increased glucose influx).
Recent evidence suggested that SGLT2 inhibitors not only have glucose-lowering effects but might also inhibit 
the progression of DN53,54. For example, empagliflozin, the first antidiabetic medication approved for reducing 
Figure 7. Effect of dapagliflozin on ER stress-mediated cell death in vivo. (a) The kidneys of db/db mice 
administered dapagliflozin were immunoblotted with indicated antibodies. (b) CHOP mRNA levels in 
the kidney of db/db mice administered dapagliflozin were determined by qRT-PCR (n = 5 independent 
experiments). (c) Caspase-3 activity levels in the kidneys of db/db mice administered dapagliflozin were 
determined (n = 5 independent experiments).
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the risk of cardiovascular death in patients with type 2 diabetes, also reduces the effects of DN54,55. Nonetheless, 
further studies are necessary to investigate the specificity of dapagliflozin for reducing the effects of DN. Future 
studies should examine whether other SGLT2 inhibitors have potentially beneficial effects on DN as well and 
determine whether inhibitors of other members of the SGLT family might have similar effects on DN.
In summary, we demonstrated that dapagliflozin lowered glucose influx in vitro and regulated ER 
stress-mediated apoptosis via regulation of elf2α-ATF4-CHOP pathway. C2 ceramide treatment on HK-2 cells 
initiated apoptosis and lipid metabolism disorder in DN. Dapagliflozin partially reduced C2 ceramide-induced 
ER stress-mediated apoptosis, which might occur in DN. In addition, dapagliflozin ameliorated ER stress in the 
kidney of db/db mice in vivo. These data suggest that dapagliflozin can be used for the prevention of DN itself.
Materials and Methods
Antibodies and reagents. Dapagliflozin and C2 ceramide were purchased from Cayman Chemical (Ann 
Arbor, MI, USA) and SIGMA-ALDRICH (St. Louis, MO, USA) respectively. Rabbit polyclonal anti-elf2α, anti-
phospho-elf2α Ser51, and anti-ATF4, and mouse monoclonal antibodies were from Cell Signaling Technology 
Inc. (Boston, MA, USA). Rabbit polyclonal anti-IRE1α and anti-phospho-IRE1α, and mouse monoclonal anti-
ATF6 antibodies were from Novus Biologicals (Littleton, CO, USA). Mouse monoclonal anti-GAPDH antibody 
was from MBL (Woods Hole, MA, USA). All other reagents were purchased from Sigma-Aldrich.
Culture and drug treatment in vitro. The human renal proximal tubular epithelial cell line HK-2 was 
obtained from ATCC (Manassas, VA, USA). The cells were cultured in a 100-cm2 dish and grown at 37 °C in 
an atmosphere of 5% CO2 in air in Keratinocyte-SFM medium supplemented with bovine pituitary extract 
(0.05 mg/mL) and epithelial growth factor (5 ng/mL; Gibco, Carlsbad, CA, USA). The glucose concentration of 
the keratinocyte-SFM medium was standard at 5.5 mmol/L. Cells were sub-cultured when they reached 70–80% 
confluence. Twenty-four hours after reseeding, the cells were treated either with dimethyl sulfoxide or 2 μM 
dapagliflozin in a serum-free culture medium for 24–48 h. As the effect of dapagliflozin was fully regulated under 
confluent conditions, each experiment was performed at confluence. For the D-galactose assay, HK-2 cells were 
incubated with the indicated concentration (0–10 mM) of D-galactose and 2 μM dapagliflozin for 48 h.
Animals. Six male db/db mice (6 each, 10–12 weeks old, weighing around 50 g, male) were housed in a facility 
with a 12-h light/dark cycle and fed a standard chow diet (Research Diets, New Brunswick, NJ) containing 67% 
(Kcal) carbohydrates, 19% protein, and 4% fat ad libitum. All studies were approved by and performed in com-
pliance with the guidelines of the institutional animal care and use committee of Gunma University. db/db mice 
were purchased from Charles River and acclimatised for 2 weeks. Dapagliflozin (0.5 mg/kg/day) dissolved with 
0.5% methylcellulose was orally administered every day for 1 week. The mice were sacrificed by cerebral disloca-
tion, and the kidneys were collected after fasting for 16 h followed by 4-h refeeding.
Western blot analysis. Proteins were extracted using a lysis buffer containing a protease inhibitor as 
described previously56 and quantified using a BCA protein assay kit (Pierce, Rockford, IL, USA). Equal amounts 
of protein were separated using 10% sodium dodecyl sulphate–polyacrylamide gel electrophoresis and electro-
phoretically transferred onto nitrocellulose membranes, which were blocked with 5% fatty acid-free powdered 
milk for 1 h. The membranes were incubated with the following primary antibodies overnight at 4 °C: anti-p-elf2α 
(1:500), anti-elf2α (1:1,000), anti-IRE1 (1:1,000), anti-p-IRE1 (1:1,000), anti-ATF6 (1:200), anti-ATF4 (1:500), 
anti-CHOP (1:500), anti-GLUT2 (1:1,000), anti-SGLT2 (1:400), and anti-tubulin-α (1:1,000); thereafter, they 
were incubated with an HRP-conjugated secondary antibody for 30 min. The membranes were extensively 
washed in tris-buffered saline with Tween 20, and antigen-antibody complexes were visualised by chemilumines-
cence using an ECL kit (Pierce).
RNA isolation and real-time qPCR. Total RNA was isolated from cells and tissues using the RNeasy 
Plus Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. Total RNA (1,000 µg) was 
reverse-transcribed using the SuperScript VILO cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, USA). Real-time 
quantitative PCR was performed on an Applied Biosystems 7500HT system (Applied Biosystems, Branchburg, 
NJ, USA) with EagleTaq Master Mix (Roche Lifescience). Gene expression levels of CHOP, ATF4, and SGLT2 
were internally normalised against those of β actin (human) and Hrpt1 (mouse) and analysed by a standard curve 
method. Each experiment was performed in triplicate and independently repeated three times.
Measurement of glucose concentration in HK2 cells. Glucose concentration was measured using the 
PicoProbe Glucose Fluorometric Assay Kit (BioVision, Milpitas, CA, USA). In brief, cells were lysed and proteins 
were incubated with the reagents provided. Samples were transferred to black-bottom 96-well microplates, and 
glucose concentrations were read at excitation and emission wavelengths of 535 and 587 nm, respectively, in a 
fluorescence microplate reader (EnSpire, Perkin Elmer). Control reactions were carried out with no protein and/
or no substrate.
Measurement of glucose influx in HK2 cells. Glucose influx was measured using a 2-Deoxyglucose 
Uptake Measurement Kit (COSMO BIO Co. Ltd., Tokyo Japan) according to the manufacturer’s instructions. 
In brief, cells were lysed and proteins were incubated with the reagents provided. Samples were transferred to 
96-well microplates, and glucose influx was read at 450 nm in a kinetic microplate reader (Molecular Devices 
Japan). Control reactions were carried out with no protein and/or no substrate.
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Measurement of caspase-3 activity in HK2 cells. Caspase-3 activity was measured using a caspase-3 
fluorescence assay kit (MBL) according to the manufacturer’s instructions. Briefly, cells and tissues were lysed 
and proteins were incubated with the caspase-3 substrate DEVD-AMC (2 μM) for 1 h at 37 °C. Samples were 
transferred to black-bottom 96-well microplates, and the relative caspase-3 activities were read at excitation and 
emission wavelengths of 380 and 460 nm, respectively, in a fluorescence microplate reader.
Knockdown of elf2α in HK2 cells. After seeding of 1.0–2.5 × 105 cells/12-well plates for 24 h, 100 nM 
siRNA for human siElF2A-lipid complexes with DharmafectDuo (Dharmacon/Thermo Scientific, Chicago, IL) 
was introduced into each well. After 24 h, the medium was replaced with dimethyl sulfoxide or 2 µM dapagli-
flozin and incubated for an additional 24 h. Knockdown efficiencies were confirmed by western blot analysis or 
real-time qPCR.
Apoptosis and necrosis assay in HK2 cells. An apoptosis and necrosis assay was performed using Cell 
Death Detection ELISAplus (Roche, Indianapolis, IN) according to the manufacturer’s instructions. In brief, after 
seeding of 1.0 × 105 cells/96-well plates for 24 h, HK-2 cells were incubated with 7.5 ng/mL C2 ceramide and 2 µM 
dapagliflozin. After 48 h, the cells were harvested to perform apoptosis and necrosis assay.
Statistics. The results are expressed as mean ± standard error of the mean. Differences between cells and/or 
treatments were tested for statistical significance (P < 0.05) using Student’s unpaired t test and ANOVA multiple 
comparisons using Tukey’s honestly significant difference test.
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article and its 
supplementary materials.
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